Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Company profile
Ticker
KDMN
Exchange
Website
CEO
Harlan W. Waksal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Kadmon Holdings, LLC
SEC CIK
Corporate docs
Subsidiaries
Kadmon Corporation, LLC • Kadmon Pharmaceuticals, LLC ...
KDMN stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
19 Nov 21
EFFECT
Notice of effectiveness
16 Nov 21
EFFECT
Notice of effectiveness
16 Nov 21
8-K
Sanofi completes acquisition of Kadmon
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Nov 21
POS AM
Prospectus update (post-effective amendment)
9 Nov 21
25-NSE
Exchange delisting
9 Nov 21
POS AM
Prospectus update (post-effective amendment)
9 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 70.94 mm | 70.94 mm | 70.94 mm | 70.94 mm | 70.94 mm | 70.94 mm |
Cash burn (monthly) | (no burn) | 3.09 mm | 11.01 mm | 10.39 mm | 9.27 mm | 8.90 mm |
Cash used (since last report) | n/a | 92.75 mm | 330.23 mm | 311.45 mm | 277.95 mm | 266.79 mm |
Cash remaining | n/a | -21.81 mm | -259.29 mm | -240.50 mm | -207.01 mm | -195.84 mm |
Runway (months of cash) | n/a | -7.0 | -23.5 | -23.2 | -22.3 | -22.0 |
Institutional ownership, Q1 2023
4.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 34.34 mm |
Total shares | 8.78 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Puissance Cross-Border Opportunities IV | 4.50 mm | $16.56 mm |
Vivo Capital VIII | 4.28 mm | $17.78 mm |